Jason R Andrews1, Elisa Nemes2, Michele Tameris2, Bernard S Landry3, Hassan Mahomed4, J Bruce McClain3, Helen A Fletcher5, Willem A Hanekom2, Robin Wood6, Helen McShane7, Thomas J Scriba2, Mark Hatherill2. 1. Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA. Electronic address: jandr@stanford.edu. 2. South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. 3. Aeras, Rockville, MD, USA. 4. Division of Community Health, Department of Interdisciplinary Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University and Metro District Health Services, Western Cape Government: Health, Cape Town, South Africa. 5. Immunology and Infection Department, London School of Hygiene & Tropical Medicine, London, UK. 6. Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa. 7. Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Abstract
BACKGROUND: The value of quantitative interferon-γ release assay results for predicting progression from Mycobacterium tuberculosis infection to active disease is unknown. We aimed to investigate the relation between QuantiFERON-TB Gold In-Tube (QFT) conversion interferon-γ values and risk of subsequent active tuberculosis disease and of QFT reversion. METHODS: We analysed data from a reported vaccine efficacy trial of the tuberculosis vaccine MVA85A in South Africa. QFT negative, HIV uninfected young children aged 18-24 weeks were enrolled. We stratified participants by quantitative QFT result (interferon-γ <0·35 IU/mL, 0·35-4·00 IU/mL, and >4·00 IU/mL) at the intermediate study visit (day 336) and determined risk of progression to active tuberculosis disease over the subsequent 6-24 months. No QFT differences were observed between placebo and MVA85A groups at day 336 or end of study; therefore, both groups were included in analyses. Study clinicians were not masked to QFT values, but strict case definitions were used that excluded QFT results. We used generalised additive models to evaluate the quantitative relation between day 336 QFT value and subsequent disease risk, and we compared disease rates between QFT strata using a two-sample Poisson test. FINDINGS: Among 2512 young children with QFT tests done at day 336, 172 (7%) were positive; 87 (7%) of 1267 in placebo group and 85 (7%) of 1245 in the MVA85A group (p=1·00). Compared with QFT non-converters (tuberculosis disease incidence 0·7 per 100 person-years [95% CI 0·4-1·1]), children with QFT conversion at interferon-γ values between 0·35-4·00 IU/mL did not have significantly increased risk of disease (2·5 per 100 person-years [95% CI 0·4-9·4]; incidence rate ratio (IRR) 3·7 (95% CI 0·4-15·8; p=0·23). However, QFT conversion at interferon-γ values higher than 4·00 IU/mL was associated with substantially increased disease incidence (28·0 per 100 person-years [95% CI 14·9-45·7]) compared with non-converters (IRR 42·5 [95% CI 17·2-99·7]; p<0·0001), and compared with children with interferon-γ values between 0·35-4·00 IU/mL (IRR 11·4 [95% CI 2·4-107·2]; p=0·00047). Among 91 QFT converters who were given a repeat test, 53 (58%) reverted from positive to negative. QFT reversion risk was inversely associated with interferon-γ value at QFT conversion and was highest with interferon-γ values less than 4·00 IU/mL (47 [77%] of 61). INTERPRETATION: In young children, tuberculosis disease risk was not significantly increased, and QFT reversion was common, following QFT conversion at interferon-γ values up to 10 times the recommended test threshold (0·35 IU/mL). By contrast, QFT conversion at very high interferon-γ values (>4·00 IU/mL) warrants intensified diagnostic and preventive intervention because of the extremely high risk of tuberculosis disease in these young children. FUNDING: Aeras, Wellcome Trust, and Oxford-Emergent Tuberculosis Consortium (OETC) were the funders of the MVA85A 020 Trial. National Institute of Allergy and Infectious Diseases supported this analysis.
BACKGROUND: The value of quantitative interferon-γ release assay results for predicting progression from Mycobacterium tuberculosis infection to active disease is unknown. We aimed to investigate the relation between QuantiFERON-TB Gold In-Tube (QFT) conversion interferon-γ values and risk of subsequent active tuberculosis disease and of QFT reversion. METHODS: We analysed data from a reported vaccine efficacy trial of the tuberculosis vaccine MVA85A in South Africa. QFT negative, HIV uninfected young children aged 18-24 weeks were enrolled. We stratified participants by quantitative QFT result (interferon-γ <0·35 IU/mL, 0·35-4·00 IU/mL, and >4·00 IU/mL) at the intermediate study visit (day 336) and determined risk of progression to active tuberculosis disease over the subsequent 6-24 months. No QFT differences were observed between placebo and MVA85A groups at day 336 or end of study; therefore, both groups were included in analyses. Study clinicians were not masked to QFT values, but strict case definitions were used that excluded QFT results. We used generalised additive models to evaluate the quantitative relation between day 336 QFT value and subsequent disease risk, and we compared disease rates between QFT strata using a two-sample Poisson test. FINDINGS: Among 2512 young children with QFT tests done at day 336, 172 (7%) were positive; 87 (7%) of 1267 in placebo group and 85 (7%) of 1245 in the MVA85A group (p=1·00). Compared with QFT non-converters (tuberculosis disease incidence 0·7 per 100 person-years [95% CI 0·4-1·1]), children with QFT conversion at interferon-γ values between 0·35-4·00 IU/mL did not have significantly increased risk of disease (2·5 per 100 person-years [95% CI 0·4-9·4]; incidence rate ratio (IRR) 3·7 (95% CI 0·4-15·8; p=0·23). However, QFT conversion at interferon-γ values higher than 4·00 IU/mL was associated with substantially increased disease incidence (28·0 per 100 person-years [95% CI 14·9-45·7]) compared with non-converters (IRR 42·5 [95% CI 17·2-99·7]; p<0·0001), and compared with children with interferon-γ values between 0·35-4·00 IU/mL (IRR 11·4 [95% CI 2·4-107·2]; p=0·00047). Among 91 QFT converters who were given a repeat test, 53 (58%) reverted from positive to negative. QFT reversion risk was inversely associated with interferon-γ value at QFT conversion and was highest with interferon-γ values less than 4·00 IU/mL (47 [77%] of 61). INTERPRETATION: In young children, tuberculosis disease risk was not significantly increased, and QFT reversion was common, following QFT conversion at interferon-γ values up to 10 times the recommended test threshold (0·35 IU/mL). By contrast, QFT conversion at very high interferon-γ values (>4·00 IU/mL) warrants intensified diagnostic and preventive intervention because of the extremely high risk of tuberculosis disease in these young children. FUNDING: Aeras, Wellcome Trust, and Oxford-Emergent Tuberculosis Consortium (OETC) were the funders of the MVA85A 020 Trial. National Institute of Allergy and Infectious Diseases supported this analysis.
Authors: Alasdair R J Bamford; Angela M Crook; Julia E Clark; Zohreh Nademi; Garth Dixon; James Y Paton; Anna Riddell; Francis Drobniewski; Andrew Riordan; Suzanne T Anderson; Amanda Williams; Sam Walters; Beate Kampmann Journal: Arch Dis Child Date: 2009-10-08 Impact factor: 3.791
Authors: Maria N Tsolia; Mersini Mavrikou; Elena Critselis; Nikolaos G Papadopoulos; Haidoniki Makrinioti; Nikolaos P Spyridis; Flora Metsou; Maria Tsagaraki; Maria Koulouri; Dimitrios A Kafetzis Journal: Pediatr Infect Dis J Date: 2010-12 Impact factor: 2.129
Authors: Madhukar Pai; Rajnish Joshi; Sandeep Dogra; Deepak K Mendiratta; Pratibha Narang; Shriprakash Kalantri; Arthur L Reingold; John M Colford; Lee W Riley; Dick Menzies Journal: Am J Respir Crit Care Med Date: 2006-05-11 Impact factor: 21.405
Authors: Roland Diel; Robert Loddenkemper; Stefan Niemann; Karen Meywald-Walter; Albert Nienhaus Journal: Am J Respir Crit Care Med Date: 2010-08-27 Impact factor: 21.405
Authors: Heather J Zar; Mark F Cotton; Stanzi Strauss; Janine Karpakis; Gregory Hussey; H Simon Schaaf; Helena Rabie; Carl J Lombard Journal: BMJ Date: 2006-11-03
Authors: Christian Lienhardt; Katherine Fielding; Abdoul A Hane; Aliou Niang; Cheikh T Ndao; Farba Karam; Helen Fletcher; Fatou Mbow; Jules-François Gomis; Raymond Diadhiou; Roger Diadhiou; Maxime Toupane; Tandakha Dieye; Souleymane Mboup Journal: PLoS One Date: 2010-05-06 Impact factor: 3.240
Authors: B J Marais; R P Gie; H S Schaaf; A C Hesseling; C C Obihara; J J Starke; D A Enarson; P R Donald; N Beyers Journal: Int J Tuberc Lung Dis Date: 2004-04 Impact factor: 2.373
Authors: B Kampmann; E Whittaker; A Williams; S Walters; A Gordon; N Martinez-Alier; B Williams; A M Crook; A-M Hutton; S T Anderson Journal: Eur Respir J Date: 2009-02-05 Impact factor: 16.671
Authors: Elisa Nemes; Virginie Rozot; Hennie Geldenhuys; Nicole Bilek; Simbarashe Mabwe; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Alana Keyser; Asma Toefy; Yolundi Cloete; Frances Ratangee; Thomas Blauenfeldt; Morten Ruhwald; Gerhard Walzl; Bronwyn Smith; Andre G Loxton; Willem A Hanekom; Jason R Andrews; Maria D Lempicki; Ruth Ellis; Ann M Ginsberg; Mark Hatherill; Thomas J Scriba Journal: Am J Respir Crit Care Med Date: 2017-09-01 Impact factor: 21.405
Authors: M E Castellanos; S Kirimunda; L Martinez; T Quach; H Woldu; R Kakaire; A Handel; S Zalwango; N Kiwanuka; C C Whalen Journal: Int J Tuberc Lung Dis Date: 2018-09-01 Impact factor: 2.373
Authors: Marc Lipman; Mahdad Noursadeghi; Ibrahim Abubakar; Rishi K Gupta; Claire J Calderwood; Alexei Yavlinsky; Maria Krutikov; Matteo Quartagno; Maximilian C Aichelburg; Neus Altet; Roland Diel; Claudia C Dobler; Jose Dominguez; Joseph S Doyle; Connie Erkens; Steffen Geis; Pranabashis Haldar; Anja M Hauri; Thomas Hermansen; James C Johnston; Christoph Lange; Berit Lange; Frank van Leth; Laura Muñoz; Christine Roder; Kamila Romanowski; David Roth; Martina Sester; Rosa Sloot; Giovanni Sotgiu; Gerrit Woltmann; Takashi Yoshiyama; Jean-Pierre Zellweger; Dominik Zenner; Robert W Aldridge; Andrew Copas; Molebogeng X Rangaka Journal: Nat Med Date: 2020-10-19 Impact factor: 53.440